Journal of Global Infectious Diseases

SYMPOSIUM - LIESHMANIASIS
Year
: 2010  |  Volume : 2  |  Issue : 2  |  Page : 159--166

Liposomal amphotericin B and leishmaniasis: Dose and response


Shyam Sundar, Jaya Chakravarty 
 Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, India

Correspondence Address:
Shyam Sundar
Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005
India

Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection. Although there is a regional variation in the susceptibility of the parasite a total dose of 20 mg/kg is effective in immunocompetent patients. Randomized clinical trials of liposomal amphotericin B in the treatment and secondary prophylaxis of HIV-VL coinfected patients is urgently needed to optimize treatment in this subset. With the availability of Liposomal amphotericin B at a preferential pricing in the endemic areas, short course combination therapy can become a viable alternative.


How to cite this article:
Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: Dose and response.J Global Infect Dis 2010;2:159-166


How to cite this URL:
Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: Dose and response. J Global Infect Dis [serial online] 2010 [cited 2020 Aug 13 ];2:159-166
Available from: http://www.jgid.org/article.asp?issn=0974-777X;year=2010;volume=2;issue=2;spage=159;epage=166;aulast=Sundar;type=0